������と����������

作者：孙梦晓 来源：本站原创 点击：3259次 更新：1523867883

　　<p style="text-align: justify;">YU Chao-chao (余超超)¹,&nbsp; &nbsp;MA Chao-yang (马朝阳)²,&nbsp; XIONG Yuan (熊&nbsp; 袁)¹,&nbsp; WU Miao (吴&nbsp; 淼)³,SHEN Feng (沈&nbsp; 峰)¹,&nbsp; ZHOU Yi-lun (周逸伦)¹,&nbsp; &nbsp;KONG Li-hong (孔立红)1 ,&nbsp; &nbsp;TANG Lei (唐&nbsp; 雷)²</p><p><br/></p><p style="text-align: justify;">1. Hubei University of Chinese Medicine, Wuhan 430061, Hubei Province, China; 2. Department of Rehabilitation, Wuhan Central Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology; 3. Department of Tuina and Rehabilitation, Hubei Provincial Hospital of TCM（1. 湖北中医药大学，湖北武汉 430061；2. 华中科技大学附属武汉市中心医院康复科；3. 湖北省中医院推拿/康复医学科)</p><p><br/></p><p><strong>ABSTRACT</strong></p><p><br/></p><p style="text-align: justify;"><strong>Objective</strong>&nbsp; This review aimed to systematically evaluate the evidence on the effects of acupoint catgut embedding (ACE) therapy for patients with polycystic ovary syndrome (PCOS). <strong>Methods</strong>&nbsp; Five databases (CBM, CNKI, Wanfang Database, VIP Database, and PubMed) were searched to identify relevant studies published before June 2017. The outcomes were resumption of menstruation and serum levels of testosterone (T). The methodological quality of the included studies was judged using the Cochrane risk of bias tool. The overall level of evidence was judged by the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) criteria. <strong>Results&nbsp;</strong> Twenty-five randomized controlled trials were included. ACE therapy significantly lowered serum T levels, and patients receiving ACE treatment reported resumption of menstruation. However, these results should be interpreted with caution due to a high risk of randomization and blinding bias, and likely publication bias. The level of evidence for resumption of menstruation and serum T levels was assessed as “low” and “low”, respectively, using GRADE. <strong>Conclusion&nbsp;</strong> The current evidence on ACE therapy for PCOS is insufficient to draw firm conclusions due to the poor methodological quality. Future well-designed trials are needed to validate the therapeutic efficacy, safety, and mechanisms of ACE in patients with PCOS.&nbsp;</p><p><br/></p><p><strong>KEY WORDS</strong>: polycystic ovary syndrome; acupoint catgut embedding; systematic review; meta-analysis</p><p><br/></p><p><strong>ABSTRACT IN CHINESE</strong></p><p style="text-align: justify;">[摘 要] 目的：系统评价穴位埋线治疗多囊卵巢综合征（PCOS）的疗效。方法：检索CBM、CNKI、WanFang数据库、VIP和PubMed中收录的关于穴位埋线治疗PCOS的临床研究文献(发表日期截止至2017年7月)。采用RevMan5.3软件进行Meta分析，采用Cochrane风险偏倚工具评估纳入研究的偏倚，采用GRADE标准评估结局指标月经周期恢复情况和雄激素水平的证据等级。结果：共纳入25个临床研究，分析结果提示穴位埋线可改善患者月经及降低雄激素水平，但其证据等级评级均为“低”，且纳入的研究存在高风险偏倚。结论：由于现存关于穴位埋线治疗PCOS的临床研究的方法学质量较低，不能对其疗效和安全性得出肯定结论，尚需要高质量、大样本的随机盲法对照试验以评估穴位埋线治疗PCOS的疗效及安全性。</p><p style="text-align: justify;">[关键词] 多囊卵巢综合征 穴位埋线 系统评价 Meta分析</p><p><br/></p>